NKTR) — Nektar Therapeutics (NASDAQ

Doris Richards
April 16, 2018

The Texas-based Hillcrest Asset Management Llc has invested 1.41% in the stock. Now the institutional investor is holding 1.03 million shares, compared to the 1.24 million from the previous quarter.

NASDAQ NKTR traded down $3.24 during trading on Friday, reaching $100.50.

Nektar Therapeutics (NASDAQ:NKTR) has been given a $89.00 target price by Mizuho in a research report issued to clients and investors on Thursday, March 29th. It has outperformed by 335.46% the S&P500. Rhumbline Advisers, a Massachusetts-based fund reported 369,568 shares. Woodley Farra Manion Portfolio Management Inc bought 4,585 shares as the company's stock declined 16.55% with the market. The institutional investor held 352,451 shares of the prepackaged software company at the end of 2017Q4, valued at $30.15M, down from 356,547 at the end of the previous reported quarter. Woodley Farra Manion Portfolio Management Inc who had been investing in British Amern Tob Plc for a number of months, seems to be bullish on the $132.52B market cap company. The "percentage off the 52-week high or low" refers to when a stock current price is relative to where it has traded over the last 52 weeks. About 535,542 shares traded. It has outperformed by 25.88% the S&P500. Therefore 100% are positive. Louisiana State Employees Retirement reported 0.18% in Nektar Therapeutics (NASDAQ:NKTR). (NYSE:GRUB) has "Buy" rating given on Monday, March 12 by Cowen & Co. HC Wainwright restated a "buy" rating and set a $125.00 price objective on shares of Nektar Therapeutics in a research note on Monday, April 2nd.

The stock has a market cap of $18.04B and the number of outstanding shares has been calculated 173.90M. Mizuho maintained the shares of NKTR in report on Friday, April 6 with "Buy" rating. The company was initiated on Tuesday, December 13 by Suntrust Robinson.

COPYRIGHT VIOLATION WARNING: "Brokerages Anticipate Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.43 Per Share" was published by StockNewsTimes and is the sole property of of StockNewsTimes. The stock has "Outperform" rating by FBR Capital on Friday, November 20. (NYSE:GRUB) earned "Buy" rating by Monness Crespi & Hardt on Monday, June 6. They expect $0.95 EPS, up 4.40% or $0.04 from last year's $0.91 per share.

Earnings per Share Details of Nektar Therapeutics: The EPS of NKTR is strolling at -0.64, measuring its EPS growth this year at 43.6%.

Nektar Therapeutics (NKTR) held 173.90 million outstanding shares now.


Shares of NASDAQ:NKTR opened at $100.50 on Thursday.

Since April 3, 2018, it had 2 buys, and 0 selling transactions for $215.07 million activity.

Professional analysts at Piper Jaffray issued "Buy" rating on Nektar Therapeutics (NASDAQ:NKTR). The Nektar Therapeutics has shown a five days performance of 2.27% and thirty days performance stands at 0.56%. Also, SVP Stephen K. Doberstein sold 2,426 shares of the business's stock in a transaction dated Friday, February 16th. Following the transaction, the director now directly owns 70,500 shares of the company's stock, valued at $4,135,530. 2,545 shares were sold by Thomsen Jillian B., worth $211,082. It's down -0.21, from 1.4 in 2017Q3. It is negative, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Investors holded 148.76 million in 2017Q3 but now own 150.36 million shares or 1.08% more. Susquehanna Intl Llp invested 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Renaissance Limited Liability Corporation, New York-based fund reported 91,848 shares. Zacks Invest Management holds 11,821 shares or 0.02% of its portfolio. World Asset Management Inc acquired 34,549 shares as Centurylink Inc Com (CTL)'s stock declined 6.44%. Artal Group Incorporated Sa holds 0.36% or 400,000 shares. Aqr Mgmt Ltd Limited Liability Company invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR).

Select Income REIT is a publicly owned equity real estate investment trust externally managed by The RMR Group LLC. Redmile Group Ltd Liability Corporation has 5,327 shares for 0.01% of their portfolio. Amalgamated Bank grew its holdings in shares of Nektar Therapeutics by 6.3% during the fourth quarter. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action. Cambridge Invest Rech Advisors Inc stated it has 3,666 shares or 0% of all its holdings.

Analysts await Select Income REIT (NASDAQ:SIR) to report earnings on April, 24. They expect $0.85 earnings per share, up 16.44% or $0.12 from last year's $0.73 per share. The firm's quarterly revenue was up 154.9% compared to the same quarter last year. sell-side analysts forecast that Nektar Therapeutics will post -1.33 EPS for the current year. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) on Thursday, January 7 with "Overweight" rating. On Wednesday, January 31 the stock rating was maintained by Credit Suisse with "Buy". The stock rating was maintained by Canaccord Genuity with "Buy" on Wednesday, January 10. The stock has "Buy" rating by Goldman Sachs on Tuesday, July 18. Canaccord Genuity has "Buy" rating and $35.0 target. KeyBanc Capital Markets maintained it with "Buy" rating and $7800 target in Sunday, July 16 report. The stock has a market capitalization of $16,694.14, a P/E ratio of -182.73 and a beta of 1.74.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER